/MIRM
MIRM Stock - Mirum Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$90.44+1.05%
+$0.94 (+1.05%) • Jan 13
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).72
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.1%upside
Target: $100.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MIRM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$89.54 – $91.34
TARGET (TP)$100.46
STOP LOSS$83.20
RISK/REWARD1:1.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.49
52W High$91.80
52W Low$36.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $336.89M | $186.37M | $77.06M | $19.14M | N/A |
| Gross Profit | $255.25M | $139.34M | $64.69M | $17.23M | $-623,000 |
| Gross Margin | 75.8% | 74.8% | 83.9% | 90.1% | N/A |
| Operating Income | $-87,606,000 | $-109,154,000 | $-131,220,000 | $-173,413,000 | $-104,296,000 |
| Net Income | $-87,942,000 | $-163,415,000 | $-135,665,000 | $-83,988,000 | $-103,270,000 |
| Net Margin | -26.1% | -87.7% | -176.0% | -438.9% | N/A |
| EPS | $-1.85 | $-4.00 | $-4.01 | $-2.77 | $-4.09 |
Company Overview
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MIRMBeat Rate
56%
Last 18 quarters
Avg Surprise
-11.1%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$0.05
Q4 2025
EPS Surprise History
Q1 24
-94.1%
$-0.66vs$-0.34
Q2 24
-35.0%
$-0.54vs$-0.40
Q3 24
-8.3%
$-0.52vs$-0.48
Q4 24
+33.3%
$-0.30vs$-0.45
Q1 25
-81.5%
$-0.49vs$-0.27
Q2 25
+23.1%
$-0.30vs$-0.39
Q3 25
+61.3%
$-0.12vs$-0.31
Q4 25
+150.0%
$0.05vs$-0.10
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.10 | $0.05 | +150.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.31 | $-0.12 | +61.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.39 | $-0.30 | +23.1% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.27 | $-0.49 | -81.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.45 | $-0.30 | +33.3% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.48 | $-0.52 | -8.3% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.40 | $-0.54 | -35.0% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.34 | $-0.66 | -94.1% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.64 | $-0.57 | +10.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.81 | $-0.92 | -13.6% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.96 | $-0.80 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | $-0.98 | $-0.99 | -1.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-1.05 | $-1.02 | +2.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-1.05 | $-0.84 | +20.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.39 | $-1.17 | +15.8% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-0.61 | $-0.92 | -50.8% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-1.63 | $-1.55 | +4.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.41 | $-1.45 | -253.7% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about MIRM
What is MIRM's current stock price?
Mirum Pharmaceuticals, Inc. (MIRM) is currently trading at $90.44 per share. The stock has moved +1.05% today.
What is the analyst price target for MIRM?
The average analyst price target for MIRM is $100.46, based on 1 analyst.
What sector is Mirum Pharmaceuticals, Inc. in?
Mirum Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MIRM's market cap?
Mirum Pharmaceuticals, Inc. has a market capitalization of $4.46 billion, making it a mid-cap company.
Does MIRM pay dividends?
No, Mirum Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$26.46
Mkt Cap: $4.5B
ADMA
ADMA Biologics, Inc.
$17.70
Mkt Cap: $4.2B
BLTE
Belite Bio, Inc
$156.95
Mkt Cap: $5.5B
DYN
Dyne Therapeutics, Inc.
$17.04
Mkt Cap: $2.4B
LGND
Ligand Pharmaceuticals Incorporated
$188.78
Mkt Cap: $3.7B
PRAX
Praxis Precision Medicines, Inc.
$280.83
Mkt Cap: $5.9B
RARE
Ultragenyx Pharmaceutical Inc.
$24.11
Mkt Cap: $2.3B
SLNO
Soleno Therapeutics, Inc.
$41.51
Mkt Cap: $2.2B
TLX
Telix Pharmaceuticals Limited
$7.45
Mkt Cap: $2.5B
TVTX
Travere Therapeutics, Inc.
$29.11
Mkt Cap: $2.6B
Explore stocks similar to MIRM for comparison